{"id":"NCT01021293","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine","officialTitle":"Immunogenicity and Safety of GSK Biologicals' IPV (Poliorix™) in Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11-28","primaryCompletion":"2010-07-05","completion":"2010-07-05","firstPosted":"2009-11-26","resultsPosted":"2017-04-25","lastUpdate":"2020-01-21"},"enrollment":1101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Poliomyelitis","Poliomyelitis Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Poliorix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Oral Poliovirus vaccine","otherNames":[]}],"arms":[{"label":"Poliorix Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the immunogenicity and safety of Poliorix™ when administered to healthy Chinese infants at 2, 3 and 4 months of age.","primaryOutcome":{"measure":"Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3","timeFrame":"At Month 3, one month after the third vaccine dose","effectByArm":[{"arm":"Poliorix Group","deltaMin":306,"sd":null},{"arm":"Control Group","deltaMin":296,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"60 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["26873055"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":550},"commonTop":["Irritability/Fussiness","Loss of appetite","Gastrointestinal symptoms","Drowsiness","Upper respiratory tract infection"]}}